Care earns SAR 318.5M in 2025; Q4 at 71M

18/02/2026 Argaam Exclusive

View other reports

National Medical Care Co. (Care) reported a net profit of SAR 318.5 million for 2025, an increase from SAR 294.7 million in the year-earlier period.

Financials (M)

Item	2024	2025	Change‬
Revenues	1,293.69	1,600.36	23.7 %
Gross Income	451.21	588.90	30.5 %
Operating Income	244.76	353.14	44.3 %
Net Income	294.70	318.47	8.1 %
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyals)	4.98	7.10	42.6 %
EPS (Riyal)	6.57	7.10	8.1 %

Revenue grew 24% year-on-year (YoY) patient volumes grew 33% to 985,088. Care also factored in higher referrals from key clients, including GOSI, MoH, government-related entities, and insurance companies.

Topline was also supported by the full-year contribution of Al Salam Hospital and continued expansion of the ReLib platform.

Cost of sales as a percentage of revenue declined to 63% from 65% in 2024, reflecting improved operating leverage and cost efficiencies.

Gross profit increased 31% YoY and gross margin expanded to 37% from 35% in 2024.

Care saw lower expected credit loss (ECL) provisions of SAR 17.8 million (FY 2024 at SAR 32.7 million), reflecting improved collection frameworks.

EBITDA grew to SAR 465.2 million from SAR 377.4 million in 2024, with EBITDA margin at 29%, largely unchanged from last year.

In 2024, Care’s net profit benefited from one-off reversals of legal and Zakat provisions amounting to SAR 72 million. Excluding these items, 2025 net profit increased by 43% YoY.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2024	Q4 2025	Change‬
Revenues	372.54	404.76	8.6 %
Gross Income	121.35	146.97	21.1 %
Operating Income	40.98	81.63	99.2 %
Net Income	83.73	70.96	(15.2 %)
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyal)	0.92	1.58	71.4 %
EPS (Riyal)	1.87	1.58	(15.2 %)

Item	Q3 2025	Q4 2025	Change‬
Revenues	412.41	404.76	(1.9 %)
Gross Income	151.47	146.97	(3.0 %)
Operating Income	90.28	81.63	(9.6 %)
Net Income	82.20	70.96	(13.7 %)
Average Shares	44.85	44.85	-
Earnings Per Share before unusual items (Riyal)	1.83	1.58	(13.7 %)
EPS (Riyal)	1.83	1.58	(13.7 %)

Q4 2025 net earnings fell 15% YoY to SAR 71 million from SAR 83.7 million a year earlier.

On a sequential basis, net profit retreated 13.7% from SAR 82.20 million in Q3.

Total shareholders’ equity, no minority interest, stood at SAR 1.84 billion by Dec. 31, 2025, compared to SAR 1.62 billion in the prior-year period.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2016	253.94	15.7 %	67.29	24.3 %	35.04	20.3 %
Q2 2016	259.77	14.0 %	84.30	29.8 %	61.24	58.0 %
Q3 2016	197.01	(6.5 %)	50.54	(0.5 %)	27.99	3.2 %
Q4 2016	189.94	(13.9 %)	4.86	(90.3 %)	(44.59)	(232.3 %)
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
Q1 2017	202.44	(20.3 %)	41.19	(38.8 %)	14.04	(59.9 %)
Q2 2017	216.54	(16.6 %)	50.25	(40.4 %)	20.01	(67.3 %)
Q3 2017	208.34	5.8 %	46.97	(7.1 %)	26.33	(5.9 %)
Q4 2017	227.76	19.9 %	57.00	1072.0 %	29.59	166.4 %
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
Q1 2018	206.67	2.1 %	51.73	25.6 %	28.41	102.4 %
Q2 2018	199.05	(8.1 %)	49.59	(1.3 %)	23.40	17.0 %
Q3 2018	176.40	(15.3 %)	33.17	(29.4 %)	13.16	(50.0 %)
Q4 2018	181.69	(20.2 %)	32.02	(43.8 %)	14.93	(49.6 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
Q1 2019	179.43	(13.2 %)	48.01	(7.2 %)	30.31	6.7 %
Q2 2019	169.94	(14.6 %)	38.26	(22.8 %)	15.56	(33.5 %)
Q3 2019	173.51	(1.6 %)	40.11	20.9 %	19.63	49.2 %
Q4 2019	185.52	2.1 %	39.27	22.6 %	22.88	53.3 %
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
Q1 2020	195.02	8.7 %	52.22	8.8 %	36.28	19.7 %
Q2 2020	186.04	9.5 %	58.87	53.9 %	29.77	91.4 %
Q3 2020	213.31	22.9 %	51.06	27.3 %	22.70	15.6 %
Q4 2020	214.60	15.7 %	61.73	57.2 %	25.36	10.9 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %
Q1 2021	214.19	9.8 %	63.64	21.9 %	42.18	16.3 %
Q2 2021	202.49	8.8 %	57.77	(1.9 %)	37.59	26.3 %
Q3 2021	213.11	(0.1 %)	63.08	23.5 %	39.80	75.3 %
Q4 2021	215.59	0.5 %	61.98	0.4 %	36.65	44.5 %
2021	845.38	4.5 %	246.47	10.1 %	156.22	36.9 %
Q1 2022	211.48	(1.3 %)	61.44	(3.5 %)	35.17	(16.6 %)
Q2 2022	216.49	6.9 %	66.80	15.6 %	45.95	22.2 %
Q3 2022	238.28	11.8 %	82.71	31.1 %	49.06	23.3 %
Q4 2022	251.69	16.7 %	78.74	27.0 %	58.74	60.3 %
2022	917.94	8.6 %	289.68	17.5 %	188.92	20.9 %
Q1 2023	261.40	23.6 %	89.88	46.3 %	58.48	66.3 %
Q2 2023	245.19	13.3 %	81.34	21.8 %	54.10	17.7 %
Q3 2023	275.36	15.6 %	91.78	11.0 %	73.90	50.6 %
Q4 2023	299.84	19.1 %	106.64	35.4 %	56.21	(4.3 %)
2023	1,081.78	17.8 %	369.63	27.6 %	242.70	28.5 %
Q1 2024	298.56	14.2 %	110.20	22.6 %	71.05	21.5 %
Q2 2024	296.82	21.1 %	108.16	33.0 %	63.18	16.8 %
Q3 2024	325.77	18.3 %	111.51	21.5 %	69.55	(5.9 %)
Q4 2024	372.54	24.2 %	121.35	13.8 %	40.98	(27.1 %)
2024	1,293.69	19.6 %	451.21	22.1 %	244.76	0.8 %
Q1 2025	385.32	29.1 %	142.98	29.7 %	96.55	35.9 %
Q2 2025	397.87	34.0 %	147.48	36.4 %	84.68	34.0 %
Q3 2025	412.41	26.6 %	151.47	35.8 %	90.28	29.8 %
Q4 2025	404.76	8.6 %	146.97	21.1 %	81.63	99.2 %
2025	1,600.36	23.7 %	588.90	30.5 %	353.14	44.3 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2016	900.65	2.5 %	206.99	(6.0 %)	94.75	(26.4 %)
2017	855.08	(5.1 %)	195.40	(5.6 %)	89.97	(5.1 %)
2018	763.80	(10.7 %)	166.51	(14.8 %)	79.90	(11.2 %)
2019	708.39	(7.3 %)	165.66	(0.5 %)	88.37	10.6 %
2020	808.95	14.2 %	223.88	35.1 %	114.11	29.1 %
2021	845.38	4.5 %	246.47	10.1 %	156.22	36.9 %
2022	917.94	8.6 %	289.68	17.5 %	188.92	20.9 %
2023	1,081.78	17.8 %	369.63	27.6 %	242.70	28.5 %
2024	1,293.69	19.6 %	451.21	22.1 %	244.76	0.8 %
2025	1,600.36	23.7 %	588.90	30.5 %	353.14	44.3 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2016	33.12	19.5 %	0.74	-	33.12	0.74
Q2 2016	59.29	40.2 %	1.32	-	59.29	1.32
Q3 2016	27.55	8.2 %	0.61	-	27.55	0.61
Q4 2016	(69.69)	(297.8 %)	(1.55)	(33.75)	(35.95)	(0.80)
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
Q1 2017	15.54	(53.1 %)	0.35	-	15.54	0.35
Q2 2017	19.50	(67.1 %)	0.43	-	19.50	0.43
Q3 2017	27.00	(2.0 %)	0.60	-	27.00	0.60
Q4 2017	23.26	133.4 %	0.52	(1.24)	24.50	0.55
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
Q1 2018	25.60	64.8 %	0.57	-	25.60	0.57
Q2 2018	20.26	3.9 %	0.45	-	20.26	0.45
Q3 2018	11.44	(57.6 %)	0.26	-	11.44	0.26
Q4 2018	4.87	(79.1 %)	0.11	-	4.87	0.11
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
Q1 2019	29.99	17.1 %	0.67	-	29.99	0.67
Q2 2019	13.81	(31.8 %)	0.31	-	13.81	0.31
Q3 2019	16.64	45.4 %	0.37	-	16.64	0.37
Q4 2019	19.64	303.2 %	0.44	-	19.64	0.44
2019	80.09	28.8 %	1.79	-	80.09	1.79
Q1 2020	33.17	10.6 %	0.74	-	33.17	0.74
Q2 2020	25.78	86.6 %	0.57	-	25.78	0.57
Q3 2020	16.32	(1.9 %)	0.36	-	16.32	0.36
Q4 2020	22.00	12.0 %	0.49	-	22.00	0.49
2020	97.27	21.4 %	2.17	-	97.27	2.17
Q1 2021	35.73	7.7 %	0.80	-	35.73	0.80
Q2 2021	30.74	19.2 %	0.69	-	30.74	0.69
Q3 2021	33.17	103.2 %	0.74	-	33.17	0.74
Q4 2021	36.71	66.9 %	0.82	-	36.71	0.82
2021	136.36	40.2 %	3.04	-	136.36	3.04
Q1 2022	30.00	(16.0 %)	0.67	-	30.00	0.67
Q2 2022	42.01	36.7 %	0.94	-	42.01	0.94
Q3 2022	42.62	28.5 %	0.95	-	42.62	0.95
Q4 2022	55.45	51.0 %	1.24	-	55.45	1.24
2022	170.07	24.7 %	3.79	-	170.07	3.79
Q1 2023	56.27	87.6 %	1.25	-	56.27	1.25
Q2 2023	47.80	13.8 %	1.07	-	47.80	1.07
Q3 2023	73.38	72.2 %	1.64	-	73.38	1.64
Q4 2023	63.48	14.5 %	1.42	-	63.48	1.42
2023	240.93	41.7 %	5.37	-	240.93	5.37
Q1 2024	81.29	44.5 %	1.81	15.84	65.45	1.46
Q2 2024	69.50	45.4 %	1.55	13.17	56.32	1.26
Q3 2024	60.19	(18.0 %)	1.34	-	60.19	1.34
Q4 2024	83.73	31.9 %	1.87	42.34	41.39	0.92
2024	294.70	22.3 %	6.57	71.35	223.35	4.98
Q1 2025	85.37	5.0 %	1.90	-	85.37	1.90
Q2 2025	79.94	15.0 %	1.78	-	79.94	1.78
Q3 2025	82.20	36.6 %	1.83	-	82.20	1.83
Q4 2025	70.96	(15.2 %)	1.58	-	70.96	1.58
2025	318.47	8.1 %	7.10	-	318.47	7.10

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2016	50.27	(61.5 %)	1.12	(33.75)	84.02	1.87
2017	85.30	69.7 %	1.90	(1.24)	86.54	1.93
2018	62.18	(27.1 %)	1.39	-	62.18	1.39
2019	80.09	28.8 %	1.79	-	80.09	1.79
2020	97.27	21.4 %	2.17	-	97.27	2.17
2021	136.36	40.2 %	3.04	-	136.36	3.04
2022	170.07	24.7 %	3.79	-	170.07	3.79
2023	240.93	41.7 %	5.37	-	240.93	5.37
2024	294.70	22.3 %	6.57	71.35	223.35	4.98
2025	318.47	8.1 %	7.10	-	318.47	7.10

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	25.56 %	21.44 %	14.91 %
Q2 2016	26.74 %	23.27 %	16.20 %
Q3 2016	27.11 %	23.91 %	16.67 %
Q4 2016	22.98 %	16.07 %	9.33 %
2016	22.98 %	17.75 %	9.33 %
Q1 2017	21.30 %	14.58 %	7.82 %
Q2 2017	18.22 %	10.27 %	3.31 %
Q3 2017	17.53 %	9.96 %	3.19 %
Q4 2017	22.85 %	18.52 %	10.12 %
2017	22.85 %	18.52 %	10.12 %
Q1 2018	23.97 %	20.17 %	11.24 %
Q2 2018	24.39 %	20.91 %	11.57 %
Q3 2018	23.64 %	20.41 %	10.10 %
Q4 2018	21.80 %	20.00 %	8.14 %
2018	21.80 %	20.00 %	8.14 %
Q1 2019	22.10 %	21.08 %	9.04 %
Q2 2019	21.41 %	21.09 %	8.50 %
Q3 2019	22.48 %	21.77 %	9.27 %
Q4 2019	23.38 %	22.17 %	11.31 %
2019	23.38 %	22.17 %	11.31 %
Q1 2020	23.46 %	22.32 %	11.50 %
Q2 2020	25.74 %	23.29 %	12.87 %
Q3 2020	25.83 %	22.00 %	12.17 %
Q4 2020	27.68 %	21.05 %	12.02 %
2020	27.68 %	21.05 %	12.02 %
Q1 2021	28.41 %	20.86 %	12.06 %
Q2 2021	27.73 %	21.19 %	12.41 %
Q3 2021	29.16 %	23.15 %	14.41 %
Q4 2021	29.15 %	24.41 %	16.13 %
2021	29.15 %	24.41 %	16.13 %
Q1 2022	28.99 %	23.58 %	15.50 %
Q2 2022	29.57 %	24.02 %	16.56 %
Q3 2022	30.95 %	24.24 %	17.16 %
Q4 2022	31.56 %	25.56 %	18.53 %
2022	31.56 %	25.56 %	18.53 %
Q1 2023	32.87 %	26.57 %	20.29 %
Q2 2023	33.38 %	26.76 %	20.28 %
Q3 2023	33.06 %	28.54 %	22.53 %
Q4 2023	34.17 %	27.51 %	22.27 %
2023	34.17 %	27.51 %	22.27 %
Q1 2024	34.85 %	28.22 %	22.35 %
Q2 2024	35.60 %	28.19 %	22.09 %
Q3 2024	35.75 %	26.90 %	20.10 %
Q4 2024	34.88 %	25.41 %	17.26 %
2024	34.88 %	25.41 %	17.26 %
Q1 2025	35.06 %	26.29 %	17.62 %
Q2 2025	35.32 %	26.48 %	18.01 %
Q3 2025	35.92 %	26.89 %	18.42 %
Q4 2025	36.80 %	28.98 %	19.90 %
2025	36.80 %	28.98 %	19.90 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2016	22.98 %	17.75 %	9.33 %
2017	22.85 %	18.52 %	10.12 %
2018	21.80 %	20.00 %	8.14 %
2019	23.38 %	22.17 %	11.31 %
2020	27.68 %	21.05 %	12.02 %
2021	29.15 %	24.41 %	16.13 %
2022	31.56 %	25.56 %	18.53 %
2023	34.17 %	27.51 %	22.27 %
2024	34.88 %	25.41 %	17.26 %
2025	36.80 %	28.98 %	19.90 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	26.50 %	20.19 %	13.04 %
Q2 2016	32.45 %	29.83 %	22.83 %
Q3 2016	25.65 %	22.64 %	13.99 %
Q4 2016	2.56 %	(15.05 %)	(18.93 %)
Q1 2017	20.35 %	15.00 %	7.68 %
Q2 2017	23.20 %	16.81 %	9.01 %
Q3 2017	22.54 %	20.74 %	12.96 %
Q4 2017	25.02 %	21.25 %	10.76 %
Q1 2018	25.03 %	21.90 %	12.39 %
Q2 2018	24.91 %	19.67 %	10.18 %
Q3 2018	18.81 %	18.43 %	6.49 %
Q4 2018	17.62 %	19.73 %	2.68 %
Q1 2019	26.76 %	26.61 %	16.71 %
Q2 2019	22.51 %	19.46 %	8.13 %
Q3 2019	23.12 %	21.16 %	9.59 %
Q4 2019	21.17 %	21.29 %	10.59 %
Q1 2020	26.78 %	26.82 %	17.01 %
Q2 2020	31.64 %	23.57 %	13.86 %
Q3 2020	23.94 %	16.85 %	7.65 %
Q4 2020	28.77 %	17.82 %	10.25 %
Q1 2021	29.71 %	25.54 %	16.68 %
Q2 2021	28.53 %	24.72 %	15.18 %
Q3 2021	29.60 %	24.62 %	15.57 %
Q4 2021	28.75 %	22.79 %	17.03 %
Q1 2022	29.05 %	22.23 %	14.19 %
Q2 2022	30.86 %	26.41 %	19.40 %
Q3 2022	34.71 %	25.37 %	17.89 %
Q4 2022	31.28 %	27.80 %	22.03 %
Q1 2023	34.38 %	26.61 %	21.53 %
Q2 2023	33.17 %	27.22 %	19.49 %
Q3 2023	33.33 %	32.22 %	26.65 %
Q4 2023	35.57 %	24.22 %	21.17 %
Q1 2024	36.91 %	29.36 %	21.92 %
Q2 2024	36.44 %	27.28 %	18.98 %
Q3 2024	34.23 %	26.75 %	18.48 %
Q4 2024	32.57 %	19.58 %	11.11 %
Q1 2025	37.11 %	31.65 %	22.15 %
Q2 2025	37.07 %	27.73 %	20.09 %
Q3 2025	36.73 %	28.23 %	19.93 %
Q4 2025	36.31 %	28.44 %	17.53 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2016	44.85	3.03	3.03	20.60
Q2 2016	44.85	3.41	3.41	21.16
Q3 2016	44.85	3.46	3.46	21.75
Q4 2016	44.85	1.12	1.87	20.18
Q1 2017	44.85	0.73	1.48	20.51
Q2 2017	44.85	(0.16)	0.59	20.93
Q3 2017	44.85	(0.17)	0.58	21.52
Q4 2017	44.85	1.90	1.93	21.98
Q1 2018	44.85	2.13	2.15	22.38
Q2 2018	44.85	2.14	2.17	21.83
Q3 2018	44.85	1.80	1.82	22.09
Q4 2018	44.85	1.39	1.39	22.23
Q1 2019	44.85	1.48	1.48	22.90
Q2 2019	44.85	1.34	1.34	22.20
Q3 2019	44.85	1.46	1.46	22.57
Q4 2019	44.85	1.79	1.79	23.03
Q1 2020	44.85	1.86	1.86	23.77
Q2 2020	44.85	2.12	2.12	22.34
Q3 2020	44.85	2.12	2.12	22.71
Q4 2020	44.85	2.17	2.17	23.12
Q1 2021	44.85	2.23	2.23	23.92
Q2 2021	44.85	2.34	2.34	23.60
Q3 2021	44.85	2.71	2.71	24.34
Q4 2021	44.85	3.04	3.04	25.07
Q1 2022	44.85	2.91	2.91	25.74
Q2 2022	44.85	3.16	3.16	25.67
Q3 2022	44.85	3.37	3.37	26.62
Q4 2022	44.85	3.79	3.79	28.17
Q1 2023	44.85	4.38	4.38	29.43
Q2 2023	44.85	4.51	4.51	29.49
Q3 2023	44.85	5.19	5.19	31.13
Q4 2023	44.85	5.37	5.37	32.41
Q1 2024	44.85	5.93	5.58	34.22
Q2 2024	44.85	6.41	5.77	33.61
Q3 2024	44.85	6.12	5.47	34.35
Q4 2024	44.85	6.57	4.98	36.26
Q1 2025	44.85	6.66	5.42	38.24
Q2 2025	44.85	6.89	5.95	38.03
Q3 2025	44.85	7.39	6.44	39.86
Q4 2025	44.85	7.10	7.10	41.23

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2016	44.85	1.12	1.87	20.18
2017	44.85	1.90	1.93	21.98
2018	44.85	1.39	1.39	22.23
2019	44.85	1.79	1.79	23.03
2020	44.85	2.17	2.17	23.12
2021	44.85	3.04	3.04	25.07
2022	44.85	3.79	3.79	28.17
2023	44.85	5.37	5.37	32.41
2024	44.85	6.57	4.98	36.26
2025	44.85	7.10	7.10	41.23

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2016	16.69	16.69	2.46
Q2 2016	18.71	18.71	3.02
Q3 2016	15.98	15.98	2.54
Q4 2016	58.81	35.19	3.27
Q1 2017	73.26	36.05	2.60
Q2 2017	NEG	79.11	2.25
Q3 2017	NEG	69.35	1.87
Q4 2017	22.90	22.57	1.98
Q1 2018	26.45	26.11	2.51
Q2 2018	27.67	27.32	2.72
Q3 2018	25.44	25.05	2.07
Q4 2018	36.28	36.28	2.26
Q1 2019	31.56	31.56	2.05
Q2 2019	43.34	43.34	2.62
Q3 2019	37.22	37.22	2.40
Q4 2019	27.22	27.22	2.11
Q1 2020	19.53	19.53	1.53
Q2 2020	19.83	19.83	1.88
Q3 2020	26.08	26.08	2.43
Q4 2020	24.62	24.62	2.31
Q1 2021	24.08	24.08	2.24
Q2 2021	29.10	29.10	2.88
Q3 2021	23.12	23.12	2.58
Q4 2021	20.59	20.59	2.50
Q1 2022	28.53	28.53	3.23
Q2 2022	17.07	17.07	2.10
Q3 2022	21.46	21.46	2.72
Q4 2022	19.49	19.49	2.62
Q1 2023	20.60	20.60	3.07
Q2 2023	28.53	28.53	4.36
Q3 2023	23.69	23.69	3.95
Q4 2023	32.47	32.47	5.38
Q1 2024	31.33	33.32	5.43
Q2 2024	33.21	36.94	6.34
Q3 2024	33.76	37.75	6.01
Q4 2024	25.32	33.41	4.61
Q1 2025	24.08	29.57	4.20
Q2 2025	23.71	27.48	4.30
Q3 2025	23.87	27.37	4.42
Q4 2025	20.02	20.02	3.46

Period	P/E	Recurring P/E	Price/book
2016	58.81	35.19	3.27
2017	22.90	22.57	1.98
2018	36.28	36.28	2.26
2019	27.22	27.22	2.11
2020	24.62	24.62	2.31
2021	20.59	20.59	2.50
2022	19.49	19.49	2.62
2023	32.47	32.47	5.38
2024	25.32	33.41	4.61
2025	20.02	20.02	3.46

Business Segments (Million)

Compared With The

Period	Medical Services	Pharmacies
Q1 2016	220.78	33.16
Q2 2016	230.14	29.62
Q3 2016	173.08	23.93
Q4 2016	162.66	27.28
Q1 2017	176.04	26.40
Q2 2017	190.13	26.41
Q3 2017	185.07	23.27
Q4 2017	202.08	25.76
Q1 2018	183.47	23.20
Q2 2018	175.85	23.20
Q3 2018	155.67	20.74
Q4 2018	154.94	26.74
Q1 2019	157.71	21.72
Q2 2019	149.87	20.07
Q3 2019	153.76	19.76
Q4 2019	162.79	22.72
Q1 2020	170.81	24.20
Q2 2020	164.47	21.52
Q3 2020	187.44	25.56
Q4 2020	192.76	22.19
Q1 2021	188.50	25.70
Q2 2021	178.18	24.30
Q3 2021	187.54	25.57
Q4 2021	188.78	26.82
Q1 2022	169.18	42.30
Q2 2022	207.43	9.06
Q3 2022	209.69	28.59
Q4 2022	221.11	30.57
Q1 2023	230.03	31.37
Q2 2023	215.77	29.42
Q3 2023	241.54	33.83
Q4 2023	264.88	34.95
Q1 2024	262.73	35.83
Q2 2024	261.20	35.62
Q3 2024	287.60	38.17
Q4 2024	330.64	41.90
Q1 2025	342.16	43.16
Q2 2025	352.53	45.35
Q3 2025	357.44	54.97
Q4 2025	363.28	41.48

Period	Medical Services	Pharmacies
2016	786.66	113.99
2017	753.32	101.85
2018	669.93	93.87
2019	624.13	84.27
2020	715.48	93.47
2021	742.99	102.39
2022	807.41	110.52
2023	952.21	129.57
2024	1,142.17	151.52
2025	1,415.41	184.95

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change
Average	86.37	70.96

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)
AlJazira Capital	83.10	70.96
Sico	86.00	70.96
United Securities Company	90.00	70.96

Financial Ratios

	Current
Market Cap (M Riyal)	5,583.83
Enterprise Value (EV) (M Riyal)	5,399.66
Shares Outstanding ((M))	44.85
EPS ( Riyal) (TTM)	7.10
Book Value (BV) ( Riyal)	41.23
Par Value ( Riyal)	10.00
Recurring P/E	17.53
P/E (TTM)	17.53
Price/book	3.02
Return on Average Assets (%) (TTM)	12.1
Return on Average Equity (%) (TTM)	18.3
EV/adj EBITDA	11.64
EV/Revenues	3.37

National Medical Care Co. (CARE)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Care earns SAR 318.5M in 2025; Q4 at 71M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2025 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

National Medical Care Co. (CARE)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Care earns SAR 318.5M in 2025; Q4 at 71M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2025

Revenue by Business Segment (Latest) 2025 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

National Medical Care Co. (CARE)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)